Reprints...

Background. Because the urine concentrations achieved by echinocandin antifungal agents are low, drugs from this class are excluded from consideration when candiduria treatment is selected. Methods. We performed a retrospective view (sponsored by Merck Research Laboratories) of case records of patients participating in phase II–III clinical studies of caspofungin to identify patients with candiduria. Results. Of 12 case records collected by Merck Research Laboratories, 6 met the criteria for significant can-diduria, allowing the evaluation of caspofungin therapy as judged by J.D.S. Three reported cases of candiduria secondary to hematogenous renal candidiasis were promptly eradicated. Of greater significance are 3 cases of complicated, ascending Candida glabrata infection (i.e., C. glabrata infection plus renal insufficiency), which were successfully treated with caspofungin. Conclusions. Caspofungin may have a role in treating complicated Candida urinary tract infections, especially when the infection is caused by non-albicans species of Candida. Management of candiduria remains immersed in con-troversy [1–4]. Much of the confusion involves deter-mining the indication for and justifying the initiation of antifungal therapy for candiduria [5]. This occurs as